Medicure Inc. reports developments tied to its U.S. pharmaceutical commercialization business, pharmacy operations, research programs, and public-company governance. The company markets and distributes AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc., and operates pharmacy businesses including Marley Drug, Gateway Medical Pharmacy, and West Olympia Pharmacy.
Recurring updates include quarterly and annual financial results, product revenue from AGGRASTAT and ZYPITAMAG, pharmacy revenue, research and development spending, and the MC-1 program for PNPO deficiency. News also covers completed pharmacy acquisitions, shareholder meeting results, conference calls, and executive leadership changes.
Medicure (MCUJF) granted stock options to certain directors, officers, employees and consultants to purchase a total of 150,000 common shares. The exercise price is $2.88 per common share.
The options vest in three equal installments on the first, second and third anniversaries of the grant date and are exercisable for five years from that date. They were granted under the company's current stock option plan. The grant is subject to TSX Venture Exchange approval.
Medicure (MCUJF) has completed enrollment of 10 patients in its Phase 3 MEND-PNPO trial of MC-1 for PNPO deficiency. Enrollment met the company's objective. Participants continue through treatment and follow-up, and several have completed study milestones. MC-1 is not FDA-approved; its safety and effectiveness have not been established.
The FDA has granted MC-1 Rare Pediatric Disease and Orphan Drug designations for seizures associated with PNPO deficiency, plus Fast Track Designation for PNPO deficiency. The European Medicines Agency has granted Orphan Drug Designation for PNPO deficiency. FDA approval of a new drug application for MC-1 in PNPO deficiency would make Medicure eligible for a Priority Review Voucher, which it could redeem or sell. Medicure plans to complete patient follow-up and advance MC-1 toward a potential application. Study design and baseline data were presented earlier this year, with the same data planned for two meetings later this year.
Medicure (MCUJF) is presenting the design, rationale and baseline data from its MEND-PNPO Phase 3 study of MC-1 for Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency at the 16th European Epilepsy Congress in Athens, Greece, held September 5-9, 2026.
MEND-PNPO is a 52-week, open-label, multi-center, externally controlled Phase 3 trial of MC-1, an oral pharmaceutical-grade pyridoxal 5'-phosphate (P5P) formulation, in patients aged 2 years and older with genetically confirmed PNPO deficiency. Enrollment began in January 2023 and is expected to complete in 2026; nine patients are enrolled and three have completed the one-year study. Baseline P5P treatment ranged from 14 to 58 mg/kg/day and steady-state P5P levels from 59.8 to 165 ng/mL, with a target enrollment of approximately 10 patients.
Medicure emphasizes that MC-1 is not FDA-approved and its safety and effectiveness have not been established.
Medicure (OTC:MCUJF, TSXV:MPH) reported Q2 2026 net revenue of $7.4 million, up from $6.7 million in Q2 2025, driven mainly by growth in its Pharmacy Business Segment, including Marley Drug, Gateway Medical Pharmacy and West Olympia Pharmacy. Pharmacy segment revenue reached $5.9 million, versus $4.2 million a year earlier, with ZYPITAMAG® pharmacy sales of $1.2 million and other pharmacy revenue of $4.7 million. ZYPITAMAG® total net revenue rose to $2.1 million, while AGGRASTAT® revenue declined to $661,000 from $1.7 million due to lower volume and generic competition. Adjusted EBITDA turned positive at $172,000 versus negative $28,000, but net loss widened to $1.4 million (–$0.14 per share), influenced by an $864,000 CMS‑related liability, higher pharmacy cost of goods sold and non‑cash amortization expenses. Unrestricted cash declined to $1.8 million from $3.8 million at December 31, 2025. The company invested $608,000 in R&D and scheduled a conference call for August 17, 2026 at 8:30 a.m. Eastern Time.
Medicure (OTC:MCUJF, TSXV:MPH) announced a CFO transition. Haaris Uddin will resign as Chief Financial Officer effective July 24, 2026 to pursue an opportunity in another industry. Board member and former CFO James Kinley has been appointed interim CFO and will assume the role after Uddin’s departure.
Medicure (OTC:MCUJF) reported Q1 2026 net revenue of $7.9 million, up from $5.4 million in Q1 2025, driven by ZYPITAMAG and the Pharmacy Business Segment. Adjusted EBITDA was $280,000, with a net loss of $406,000 ($0.04/share) and R&D spending of $855,000.
AGGRASTAT revenue declined to $979,000, while unrestricted cash fell to $1.5 million at March 31, 2026. A conference call is scheduled for May 25, 2026.
Medicure (OTC:MCUJF, TSXV:MPH) reported results of its May 21, 2026 Annual General Meeting and the appointment of Kerrie Hayes as a new independent director.
Shareholders holding 5,237,796 shares, or 50.19% of outstanding shares, voted and approved all resolutions, including director elections and auditor reappointment. Long‑serving director Peter Quick stepped down.
Medicure (OTC:MCUJF) reported 2025 results and scheduled a conference call for April 27, 2026 at 8:30 AM ET.
Key metrics: total net revenue $28.9M (2025) vs $21.9M (2024); AGGRASTAT sales $5.7M; Pharmacy revenue $20.3M; ZYPITAMAG sales $6.5M; R&D $3.2M; Adjusted EBITDA -$1.5M; Net loss $7.1M ($0.68/share); cash $3.8M.
Medicure (OTC:MCUJF) announced that Dr. Neil Owens has resigned as President and Chief Operating Officer, effective on or before May 31, 2026.
Dr. Albert D. Friesen, CEO and chair, will assume the responsibilities of President to maintain continuity while the company continues executing its strategic priorities.
Medicure (OTC:MCUJF) reported Q3 2025 results for the quarter ended September 30, 2025. Total net revenue was $8.2M vs $5.2M a year earlier, driven by pharmacy acquisitions and increased ZYPITAMAG® sales. AGGRASTAT® revenue fell to $1.0M from $1.9M amid generic pricing pressure. Adjusted EBITDA was negative $597k and net loss was $1.4M (‑$0.13/share) versus net income $680k (0.07/share) in Q3 2024. Unrestricted cash was $4.1M at Sept 30, 2025, down from $7.2M at Dec 31, 2024. R&D investment was $717k, supporting a Phase 3 trial for MC-1 for PNPO deficiency.